Nurix Therapeutics Price Target Maintained With a $30.00/Share by BTIG
BTIG has maintained its price target for Nurix Therapeutics at $30.00 per share. This indicates a continued positive outlook on the company's valuation from the investment firm.
A Look At Nurix Therapeutics (NRIX) Valuation After New NX-5948 Data And EHA Congress Selection
Nurix Therapeutics (NRIX) is under scrutiny after releasing new data for its BTK degrader NX-5948 and securing an oral presentation at the EHA Congress. Despite strong long-term returns, the stock has recently pulled back, and its current Price-to-Sales ratio of 22.8x suggests it is overvalued compared to its peers and fair value estimates. Analysts anticipate continued revenue growth but expect the company to remain unprofitable for the next three years, indicating that considerable optimism is already factored into its share price.
Nurix Therapeutics : NRIX
Nurix Therapeutics Inc. (NRIX) is a clinical-stage biopharmaceutical company focused on developing new treatments for cancer, inflammatory conditions, and other diseases. They specialize in small molecule and cell therapies, including those for B-cell malignancies, autoimmune diseases, and immuno-oncology, and have collaborations with major industry players like Gilead Sciences and Sanofi. The article highlights their current stock data, showing NRIX at $15.55, up 1.94%.
Nurix Therapeutics (NRIX) director awarded 31,250 stock options at $15.86 strike
Nurix Therapeutics director Paul M. Silva was granted 31,250 stock options with an exercise price of $15.86 per share, expiring on May 14, 2036. These options will vest fully on the earlier of the company's next annual stockholder meeting or May 15, 2027, provided Silva continues his service. This transaction increases his direct holdings of stock options to 31,250 shares.
Nurix Therapeutics (NRIX) director receives 31,250-share stock option grant
Nurix Therapeutics, Inc. director Judith A. Reinsdorf received a grant of stock options for 31,250 shares of common stock. The options have an exercise price of $15.86 per share and expire on May 14, 2036. The entire award vests 100% on the earlier of the company's next annual stockholder meeting or May 15, 2027, subject to her continued service.
Nurix Therapeutics (NRIX) shareholders approve directors, PwC audit and say-on-pay
Nurix Therapeutics, Inc. (NRIX) shareholders approved the election of three Class III directors, ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm, and endorsed executive compensation on a non-binding advisory basis during their 2026 annual meeting. The meeting had a quorum with over 80% of voting power represented, and all proposals passed. This information was detailed in a recent 8-K filing.
Nurix Therapeutics (NRIX) director awarded 31,250 stock options
Nurix Therapeutics (NRIX) director Julia P. Gregory was granted 31,250 stock options with an exercise price of $15.86 per share, expiring on May 14, 2036. This grant is compensation-related and vests 100% on the earlier of the next annual stockholder meeting or May 15, 2027, contingent on her continued service. The transaction is documented in a recent SEC Form 4 filing.
Nurix Therapeutics (NRIX) director receives grant of 31,250 stock options at $15.86
Nurix Therapeutics director David L. Lacey was granted 31,250 stock options with an exercise price of $15.86 per share. These options will vest fully on the earlier of the next annual stockholder meeting or May 15, 2027, provided he continues his service to the company. The options are set to expire on May 14, 2036.
Nurix Therapeutics (NRIX) director gets 31,250 stock options at $15.86
Nurix Therapeutics director Roger D. Dansey was granted 31,250 stock options with an exercise price of $15.86 per share. This compensation-related award vests 100% on the earlier of the next annual stockholder meeting or May 15, 2027, provided Dansey continues his service. The options are set to expire on May 14, 2036.
Nurix Therapeutics (NRIX) director awarded 31,250 stock options
Nurix Therapeutics director Roy D. Baynes was granted 31,250 stock options with an exercise price of $15.86 per share, expiring on May 14, 2036. The options will fully vest on the earlier of the company's next annual stockholder meeting or May 15, 2027, provided Baynes continues his service. This grant increases his direct holdings of derivative securities linked to Nurix common stock to 31,250 shares.
Nurix Therapeutics Shareholders Back Directors and Governance Proposals
Nurix Therapeutics shareholders re-elected three Class III directors and approved PwC as their independent auditor during their 2026 Annual Meeting. They also gave advisory approval for executive compensation, indicating strong confidence in the company's governance and financial oversight. Despite weak financial performance, primarily due to large losses, TipRanks' AI Analyst Spark rates NRIX as Neutral, citing a low-leverage balance sheet and neutral technical indicators.
Deep Track files 6.17% ownership in Nurix Therapeutics (NRIX) — 6.35M shares
Deep Track Capital, Deep Track Biotechnology Master Fund, and David Kroin have reported a beneficial ownership of 6,345,244 shares, representing 6.17% of Nurix Therapeutics (NRIX) Common Stock. This stake is a passive investment, as indicated by a Schedule 13G/A filing made as a joint filing under Rule 13d-1(k). The percentage is based on 102,843,012 shares outstanding as of January 23, 2026.
Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting
Nurix Therapeutics announced new preclinical and Phase 1 data for bexobrutideg, a Bruton's tyrosine kinase (BTK) degrader, for chronic spontaneous urticaria (CSU). The data presented at the 2026 Society for Investigative Dermatology Annual Meeting indicate that bexobrutideg provides potent and selective BTK degradation, offering deeper suppression of immune signaling compared to BTK inhibitors. Nurix believes this research supports further clinical development of bexobrutideg for inflammatory and immunological conditions.
Did Nurix’s (NRIX) EHA Oral BTK Degrader Data Just Reframe Its Oncology Investment Narrative?
Nurix Therapeutics announced its CEO will participate in upcoming healthcare conferences and that new efficacy and safety data for its oral BTK degrader, bexobrutideg (NX-5948), in chronic lymphocytic leukemia will be presented at the 2026 European Hematology Association Congress. While this news doesn't fundamentally alter Nurix's investment narrative, it increases attention on its clinical readouts and financing needs for its targeted protein degradation pipeline. The company faces high cash burn and unprofitability, making clinical success and funding crucial for its valuation.
Experimental hives pill from Nurix shows 25x lab potency vs remibrutinib
Nurix Therapeutics announced new preclinical and Phase 1 translational data for its oral BTK degrader, bexobrutideg (NX-5948), for chronic spontaneous urticaria (CSU). The data showed that bexobrutideg achieved approximately 25-fold greater potency than remibrutinib in preclinical models and demonstrated rapid, robust BTK degradation in healthy volunteers. These findings support its continued clinical development in CSU and broader inflammation and immunology indications, highlighting the potential for deeper and more durable suppression of pathogenic signaling compared to traditional BTK inhibitors.
Nurix Therapeutics stock (US67079U1007): Analysts see 144% upside potential
Nurix Therapeutics (NRIX) shares are projected by Wall Street analysts to have an average 12-month price target of $27.07, representing a 144.06% upside from its October 2025 closing price. The company, a clinical-stage biopharmaceutical firm, focuses on developing protein modulation therapies for cancer and inflammatory diseases. Analysts have given the stock a 'Moderate Buy' rating, highlighting its potential in the innovative biotech sector.
Nurix Therapeutics, Inc. - Common stock (NQ: NRIX) News
This article provides a list of recent news headlines related to Nurix Therapeutics, Inc. (NRIX), including stock performance, analyst rating changes, and early clinical trial data. Many headlines from October 2021 focus on the positive impact of encouraging data from a Phase 1a trial for their lead therapy, a BTK inhibitor for blood cancers, leading to increased stock prices and raised price targets from analysts. Earlier headlines from April and July 2021 also discuss stock movements and return on capital employed insights.
Nurix stock delivers 64% return after Fair Value identified opportunity
Nurix Therapeutics (NASDAQ:NRIX) has delivered a significant 63.93% return since InvestingPro’s Fair Value models identified it as undervalued in February 2024. The stock, initially trading 49% below its intrinsic value, rose from $9.87 to $16.18, validating the analysis, which uses multiple valuation methodologies. Despite typical biotech volatility, recent developments like a pivotal Phase 2 study and Sanofi extending a license option have reinforced the investment thesis, with analysts maintaining price targets up to $41.
Nurix Therapeutics to Participate in Upcoming Investor Conferences
Nurix Therapeutics, Inc. announced that its President and CEO, Arthur T. Sands, will participate in fireside chats at the upcoming RBC Global Healthcare Conference on May 20, 2026, and the Jefferies Global Healthcare Conference on June 3, 2026. The company is a clinical-stage biopharmaceutical firm focused on targeted protein degradation medicines for oncology and autoimmune diseases. Webcasts of these events will be available in the Investors section of Nurix's website.
Vanguard Group Inc. Purchases 1,460,736 Shares of Nurix Therapeutics, Inc. $NRIX
Vanguard Group Inc. significantly increased its stake in Nurix Therapeutics ($NRIX) by 32.5% in the fourth quarter, acquiring an additional 1.46 million shares, bringing its total holdings to 5.95 million shares valued at $112.9 million. Despite this large investment, analysts have a "Moderate Buy" consensus rating with an average price target of $30.46, though the company recently reported a wider-than-expected loss and lower-than-anticipated revenue. Insider trading also saw sales of stock by the CFO and an insider, while the stock trades below its 200-day moving average.
Nurix CEO to speak at two May–June healthcare investor events
Nurix Therapeutics announced that its President and CEO, Arthur T. Sands, will participate in fireside chats at two upcoming investor conferences: the RBC Global Healthcare Conference on May 20, 2026, and the Jefferies Global Healthcare Conference on June 3, 2026. The company, a clinical-stage biopharmaceutical firm, will provide live and archived webcasts of these sessions in the Investors section of its website for 30 days. These events offer insights into Nurix's advancements in targeted protein degradation medicines for oncology and autoimmune diseases.
Nurix Therapeutics to present new Phase 1a b data on BTK degrader NX-5948 in CLL at EHA2026
Nurix Therapeutics announced it will present updated efficacy and safety data from its Phase 1a/b clinical trial of the BTK degrader bexobrutideg (NX-5948) in patients with chronic lymphocytic leukemia (CLL) at EHA2026. This oral presentation, scheduled for June 11-14, 2026, is expected to offer new insights into the clinical performance and safety profile of NX-5948 for CLL treatment. The trial underscores Nurix's commitment to advancing new therapies for hematologic malignancies.
Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress
Nurix Therapeutics announced that an abstract highlighting updated efficacy and safety data for its BTK degrader, bexobrutideg (NX-5948), in patients with chronic lymphocytic leukemia (CLL) has been accepted for oral presentation at the 31st European Hematology Association Congress (EHA2026). The presentation will detail findings from an ongoing Phase 1a/b trial of bexobrutideg across various lines of therapy for CLL. Bexobrutideg is an investigational, orally bioavailable, brain-penetrant BTK degrader currently undergoing evaluation in both pivotal single-arm Phase 2 and Phase 1a/1b clinical trials for B cell malignancies.
A Look At Nurix Therapeutics (NRIX) Valuation After Recent Share Price Move
Nurix Therapeutics (NRIX) has seen recent investor attention following a share price move, prompting a review of its valuation. The company, a clinical-stage biopharmaceutical firm, is currently trading at a 23.8x Price-to-Sales multiple despite being loss-making, which is higher than the broader US Biotech industry average but lower than its direct peer average. Analysts anticipate annual revenue growth of around 42.2%, suggesting potential for future growth although the current P/S ratio is considered overvalued due to reliance on early-stage clinical programs.
A Look At Nurix Therapeutics (NRIX) Valuation After Recent Share Price Move
Nurix Therapeutics (NRIX) has seen recent investor attention due to its share price movement. Despite an expensive Price-to-Sales (P/S) multiple of 23.8x, the company, in a loss-making position, is trading at a discount to analyst targets, with analysts expecting 42.2% annual revenue growth. The article suggests investors examine underlying data and consider both potential rewards and warning signs before making investment decisions.
Nurix Therapeutics stock (US67079U1007): Biotech firm trading with deep losses and cash cushion
Nurix Therapeutics (NRIX) trades on Nasdaq with a market cap of approximately $1.9 billion, despite reporting significant operating losses and negative margins. The biotechnology company focuses on developing targeted protein degraders for oncology and immune-mediated diseases, relying on collaboration and licensing agreements for revenue. With a net cash position of over $370 million, the firm has a buffer for R&D, but its value is highly dependent on clinical trial outcomes and regulatory approvals.
Number of shareholders of Nurix Therapeutics, Inc. – NASDAQ:NRIX
This article provides details on the number of shareholders for Nurix Therapeutics, Inc. (NASDAQ: NRIX). It includes a table with period, value, and change information, and states that market data is provided by ICE Data Services and FactSet. The content is primarily a data page from TradingView.
FMR LLC Boosts Position in Nurix (NRIX) — 5.54M Shares Reported
FMR LLC has filed a Schedule 13G, disclosing beneficial ownership of 5,541,271.11 shares, or 5.4%, of Nurix Therapeutics (NRIX) common stock as of March 31, 2026. This filing indicates a passive investment status, with FMR LLC and Abigail P. Johnson reported to have sole dispositive and voting power over these shares. The disclosure emphasizes transparency regarding significant ownership stakes in publicly traded companies.
Nurix Therapeutics (NRIX) CFO sells 14,055 shares in planned trade
Nurix Therapeutics' Chief Financial Officer, Hans van Houte, sold a total of 14,055 shares of common stock on May 5, 2026, through two open-market transactions. These sales were conducted under a pre-adopted Rule 10b5-1 trading plan. The shares were sold at weighted average prices of $16.5756 and $17.1751, totaling approximately $233,319.
Houte Hans Van Sells 14,055 Shares of Nurix Therapeutics (NASDAQ:NRIX) Stock
Nurix Therapeutics CFO Houte Hans Van sold 14,055 shares of company stock on May 5th at an average price of $16.60, reducing his stake by over 27% under a pre-arranged Rule 10b5-1 plan. This sale follows another transaction on April 30th. Despite the insider selling and recent weaker-than-expected quarterly earnings, analysts maintain a "Moderate Buy" consensus rating with a target price of $30.46 for NRIX.
Nurix CFO Hans van Houte sells $233k in company stock
Nurix Therapeutics CFO Hans van Houte sold 14,055 shares of company stock across two transactions on May 5, 2026, totaling $233,318. These sales were executed under a Rule 10b5-1 trading plan. Following the transactions, van Houte directly holds 37,592 shares, while the company has recently received reiterated "Buy" and "Outperform" ratings from analysts and presented preclinical oncology data.
Insider Sell: Christine Ring Sells Shares of Nurix Therapeutics Inc (NRIX)
Christine Ring, Chief Legal Officer of Nurix Therapeutics Inc (NRIX), sold 8,148 shares of the company on May 4, 2026, reducing her holdings to 18,305 shares. This sale is part of a trend of 22 insider sells and no insider buys at Nurix Therapeutics over the past year. The stock was trading at $16.96 per share, making it significantly overvalued according to GuruFocus's GF Value of $9.36.
[144] Nurix Therapeutics, Inc. SEC Filing
Nurix Therapeutics, Inc. (NRIX) filed a Form 144 with the SEC on May 5, 2026, indicating a proposed sale of 14,055 shares of common stock with an aggregate market value of $237,951.15. The securities were acquired on January 30, 2026, as Restricted Stock Units from the Issuer. Morgan Stanley Smith Barney LLC Executive Financial Services is listed as the broker for the transaction.
Nurix Therapeutics chief legal officer sells $138k in stock By Investing.com
Nurix Therapeutics' Chief Legal Officer, Christine Ring, sold 8,148 shares of common stock for approximately $138,209 on May 4, 2026, as part of a pre-planned trading strategy. This transaction leaves her with 18,305 shares. The sale occurred while the stock has seen a 50% return over the past year, though InvestingPro suggests it is currently slightly undervalued.
Nurix Therapeutics chief legal officer sells $138k in stock
Christine Ring, Chief Legal Officer at Nurix Therapeutics (NASDAQ:NRIX), sold 8,148 shares of common stock for approximately $138,209 on May 4, 2026, pursuant to a Rule 10b5-1 trading plan. Despite this insider sale, NRIX shares are trading near $16.93 and have shown a 50% return over the past year, with InvestingPro analysis suggesting they are slightly undervalued. The company has also been presenting preclinical data at scientific meetings and receiving reaffirmed "Buy" and "Outperform" ratings from analysts, with multiple catalysts expected in 2026.
Nurix Therapeutics chief legal officer sells $138k in stock
Nurix Therapeutics' Chief Legal Officer, Christine Ring, sold 8,148 shares of NRIX stock for approximately $138,209, as part of a Rule 10b5-1 trading plan. Despite the insider sale, NRIX shares have shown a 50% return over the past year and are considered slightly undervalued by InvestingPro. Analysts from H.C. Wainwright, Piper Sandler, and RBC Capital have reiterated positive ratings and price targets for Nurix, citing progress in its oncology programs and upcoming catalysts in 2026.
Nurix Therapeutics (NRIX) CLO sells 8,148 shares in planned trade
Nurix Therapeutics' Chief Legal Officer, Christine Ring, sold 8,148 shares of common stock at a weighted average price of $16.9624 per share through a pre-arranged Rule 10b5-1 trading plan. Following this planned open-market sale, she retains 18,305 shares in the company. The transaction, classified as a moderate impact with negative sentiment, aims to provide liquidity while maintaining a significant equity stake.
Form 144: Christine Ring to sell NRIX shares (NRIX)
Christine Ring, an affiliate of Nurix Therapeutics, Inc. (NRIX), filed a Form 144 indicating her intent to sell 8,148 shares of NRIX common stock. The filing also detailed several previous 10b5-1 sales by Ring in early 2026, totaling significant share counts and proceeds. These securities originated from Restricted Stock Units dated May 2, 2022.
Nurix Therapeutics (NASDAQ:NRIX) CFO Houte Hans Van Sells 2,388 Shares
Nurix Therapeutics CFO Houte Hans Van sold 2,388 shares of NRIX stock to cover tax withholding obligations, reducing his stake by 4.42%. Despite the company missing its latest quarterly earnings and revenue expectations, analysts maintain a "Moderate Buy" consensus rating with an average price target of $30.46, significantly higher than its current trading price of $16.70. Several institutional investors have recently adjusted their positions in Nurix Therapeutics.
Nurix Therapeutics CLO Christine Ring sells $90,406 in stock
Christine Ring, CLO at Nurix Therapeutics (NASDAQ:NRIX), sold 5,394 shares for $90,406 on May 1, 2026, as part of a Rule 10b5-1 trading plan. The sale follows significant stock gains and leaves her with 26,453 shares. Analysts from H.C. Wainwright, Piper Sandler, and RBC Capital have reiterated "Buy" or "Outperform" ratings for NRIX, with price targets ranging from $30 to $35, citing clinical advancements and strong growth prospects.
Nurix Therapeutics (NRIX) legal chief sells 5,394 shares in planned trade
Nurix Therapeutics' Chief Legal Officer, Christine Ring, sold 5,394 shares of common stock on May 1, 2026, as part of a pre-arranged Rule 10b5-1 trading plan. The shares were sold at a weighted average price of $16.7606, totaling approximately $90,407. Following this transaction, Ring directly holds 26,453 shares of the company's common stock.
Issuer (NASDAQ: NRIX) reports proposed RSU sale by executive
Nurix Therapeutics, Inc. (NASDAQ: NRIX) executive Christine Ring has filed a Form 144 indicating proposed sales of 5,394 Restricted Stock Units (RSUs) with an effective date of April 30, 2026. The filing details multiple 10b5-1 sales planned or executed between February and April 2026, totaling significant share counts and proceeds. This type of filing ensures transparency regarding insider stock sales.
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Nurix Therapeutics, Inc. (NASDAQ:NRIX) has received a consensus "Moderate Buy" recommendation from fifteen analysts, with an average 12-month target price of $30.46, significantly higher than its recent opening of $16.70. Despite this positive outlook, the company reported weak quarterly results, missing EPS and revenue estimates, and remains unprofitable. Insider activity shows some selling to cover tax obligations, while institutional investors, including Millennium Management and Goldman Sachs, have increased their positions.
Nurix therapeutics CSO Hansen sells $53,497 common stock
Gwenn Hansen, CSO of Nurix Therapeutics (NASDAQ:NRIX), sold 3,214 shares worth $53,497 to cover tax obligations from RSU vesting on April 30, 2026. This was not a discretionary trade, and on the same day, she acquired 8,608 shares through RSU vesting. Analysts remain optimistic about NRIX, with price targets ranging from $23 to $41, reflecting confidence in its oncology pipeline and recent preclinical data presentations.
Nurix (NRIX) CFO nets shares after RSU vesting tax sale
Nurix Therapeutics' CFO, Hans van Houte, reported that 8,608 restricted stock units (RSUs) vested on April 30, 2026. To cover tax withholding obligations associated with this vesting, 2,388 common shares were sold at a weighted average price of $16.6453 per share in a "sell to cover" transaction, which was not a discretionary trade. Following these transactions, van Houte directly holds 51,647 shares of Nurix common stock.
Nurix (NRIX) CSO Hansen converts RSUs, sells 3,214 shares to cover taxes
Nurix Therapeutics' Chief Scientific Officer, Gwenn Hansen, recently converted restricted stock units (RSUs) into 8,608 shares of common stock. On the same day, she sold 3,214 shares at an average price of $16.6453 per share. This sale was not discretionary but rather a "sell to cover" transaction to fulfill tax withholding obligations under the company’s equity incentive plans, leaving her with 120,399 directly held common shares.
Nurix therapeutics CFO Hans van Houte sells $39,748 in shares
Nurix Therapeutics CFO Hans van Houte sold 2,388 shares worth $39,748 to cover tax obligations from vested restricted stock units, not due to discretionary trading. Concurrently, he acquired 8,608 shares through RSU vesting, bringing his total direct holdings to 51,647 shares. Various analysts have reiterated positive ratings and price targets for NRIX, citing upcoming catalysts and clinical progress in chronic lymphocytic leukemia.
Insider Selling: Nurix Therapeutics (NASDAQ:NRIX) Insider Sells 3,214 Shares of Stock
Nurix Therapeutics insider Gwenn Hansen recently sold 3,214 shares of the company's stock at an average price of $16.65, totaling $53,513.10, to cover tax withholding obligations. This transaction reduced her stake by 2.6% to 120,399 shares. The company's stock is trading near $16.70 after reporting Q1 EPS of ($0.79) and revenue of $6.25M, both missing estimates, yet analysts maintain a "Moderate Buy" rating with a $30.46 target price.
Pictet Asset Management Holding SA Acquires 1,487,060 Shares of Nurix Therapeutics, Inc. $NRIX
Pictet Asset Management Holding SA significantly increased its stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) during the fourth quarter, acquiring an additional 1,487,060 shares and now owning 3,467,600 shares valued at approximately $65.78 million. This comes as Nurix reported a quarterly EPS miss and lower-than-expected revenue. Despite mixed analyst sentiment, the stock holds an average "Moderate Buy" rating with an average price target of $30.46, though insiders have recently sold shares.
California Biopharma Co. Uncovers Massive Oncology Breakthrough
Nurix Therapeutics Inc. (NRIX:NASDAQ) has released new preclinical data for its oncology pipeline, showcasing advancements in targeted protein degradation for cancer treatment. These presentations at AACR 2026 highlighted programs for pan-mutant BRAF, CBL-B, and Aurora Kinase A (AURKA), aiming to overcome limitations of current therapies. Analysts view these developments positively, with several firms reiterating "Buy" ratings and projecting significant upside potential for the company's stock.
